B. Riley Has Bullish Estimate for Vaxart FY2024 Earnings

Vaxart, Inc. (NASDAQ:VXRT) – Equities research analysts at B. Riley boosted their FY2024 earnings per share (EPS) estimates for Vaxart in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings per share of ($0.40) for the year, up from their previous forecast of ($0.54). The consensus estimate for Vaxart’s current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart’s Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.27) EPS and FY2026 earnings at ($0.28) EPS.

Separately, Oppenheimer assumed coverage on shares of Vaxart in a research note on Thursday, August 15th. They issued an “outperform” rating and a $4.00 price target for the company.

Vaxart Price Performance

Shares of VXRT opened at $0.61 on Thursday. Vaxart has a one year low of $0.52 and a one year high of $1.54. The stock has a 50-day moving average price of $0.79 and a 200 day moving average price of $0.77.

Institutional Trading of Vaxart

Several hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in Vaxart in the 1st quarter worth approximately $20,000,000. Vanguard Group Inc. raised its holdings in Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock worth $10,984,000 after buying an additional 1,404,391 shares during the period. Millennium Management LLC lifted its position in shares of Vaxart by 110.8% in the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after acquiring an additional 2,095,274 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock valued at $2,160,000 after purchasing an additional 346,725 shares in the last quarter. Finally, Monaco Asset Management SAM purchased a new stake in Vaxart in the 2nd quarter worth about $402,000. Institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.